Things Worth Noting
A phase III trial presented at ESMO 2025 shows that combining enzalutamide with hormone therapy (ADT) cuts the risk of death by over 40% in men with advanced prostate cancer that returns after surgery or radiation. The EMBARK trial, involving 1,068 men, tested enzalutamide plus leuprolide, leuprolide alone, or enzalutamide monotherapy in high-risk, biochemically recurrent […]
Prostate cancer, a common cancer in men, often grows slowly but can become aggressive, spreading to other areas. It affects the prostate gland, which produces seminal fluid. Risk factors include age (over 65), African descent, family history, obesity, smoking, and poor diet. Early stages may show no symptoms, but later signs include trouble urinating, frequent […]